- Edwards Lifesciences' (NYSE:EW) Conservative Accounting Might Explain Soft Earnings
May 13, 2026
Soft earnings didn't appear to concern Edwards Lifesciences Corporation's (NYSE:EW) shareholders over the last week. We did some digging, and we believe the earnings are stronger than they seem.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NYSE:EW Earnings and Revenue History May 13th 2026
The Impact Of Unusual Items On Profit
To properly understand Edwards Lifesciences' profit results, we need to consider the US$662m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Edwards Lifesciences to produce a higher profit next year, all else being equal.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Edwards Lifesciences' Profit Performance
Because unusual items detracted from Edwards Lifesciences' earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Edwards Lifesciences' earnings potential is at least as good as it seems, and maybe even better! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Case in point: We've spotted 3 warning signs for Edwards Lifesciences you should be aware of.
This note has only looked at a single factor that sheds light on the nature of Edwards Lifesciences' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments
- Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise
May 11, 2026
Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. A copy of the letter is available to download here. In Q1 2026, the Artisan Mid Cap Fund reported negative absolute returns but slightly outperformed the Russell Midcap® Growth Index. The market favored lower volatility and income-oriented equities, with value outpacing growth significantly. Despite challenges for growth strategies, selective stock choices in sectors like industrials and healthcare provided strength, while consumer discretionary faced weaknesses. Mid- and small-cap indices showed resilience amid lagging large-cap growth stocks. The escalating conflict in Iran influenced market behavior, and AI-related investments continued to support capital spending and earnings. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Fund highlighted stocks like Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) is a leading medical technology company specializing in the treatment of advanced cardiovascular diseases. On May 8, 2026, Edwards Lifesciences Corporation (NYSE:EW) closed at $79.96 per share. One-month return of Edwards Lifesciences Corporation (NYSE:EW) was 2.36%, and its shares gained 6.90% over the past 52 weeks. Edwards Lifesciences Corporation (NYSE:EW) has a market capitalization of $46.04 billion.
Artisan Mid Cap Fund stated the following regarding Edwards Lifesciences Corporation (NYSE:EW) in its Q1 2026 investor letter:
"We also added to Edwards Lifesciences Corporation (NYSE:EW), Waters and Arthur J. Gallagher during the quarter. Edwards Lifesciences designs, develops, manufactures and markets products and services for the treatment of late-stage cardiovascular disease. The company has a long history of leadership in heart valve replacement products and is the market leader in minimally invasive valves delivered via catheters. We added to the position as the core aortic valve franchise has been reaccelerating and demand for newer tricuspid valves has been rapidly growing, expanding Edwards’ addressable market. This next product cycle is supported by strong clinical data and increasing physician adoption, with Edwards gaining share as competing solutions have struggled to match its clinical outcomes. After several years of heavy investment to support long-term growth, we expect stronger revenue growth to drive margin expansion."
Story Continues
Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone”
Edwards Lifesciences Corporation (NYSE:EW) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 64 hedge fund portfolios held Edwards Lifesciences Corporation (NYSE:EW) at the end of the fourth quarter, the same as in the previous quarter. While we acknowledge the potential of Edwards Lifesciences Corporation (NYSE:EW) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
In another article, we covered Edwards Lifesciences Corporation (NYSE:EW) and shared the list of best medical device stocks to invest in. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
View Comments
- Edwards Lifesciences Announces Appointment of CFO
May 4, 2026
IRVINE, Calif., May 04, 2026--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora ("Doretta") Mistras as the company’s corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role.
Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company’s global finance organization and overseeing financial planning, reporting and operational finance across a complex, global business. Prior to Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets, and earlier in her career held senior leadership roles in healthcare investment banking at Goldman Sachs. Mistras brings decades of healthcare leadership experience helping guide corporate boards and executive teams on corporate finance, strategy and investor relations. She holds a bachelor’s degree in international studies from the University of Pennsylvania and a bachelor’s degree in economics from the Wharton School.
"We are very pleased to welcome Doretta to Edwards as our next CFO," said Bernard Zovighian, Edwards’ CEO. "Doretta’s broad experience will be instrumental as we execute our differentiated strategy. We look forward to her leadership as we continue to invest in innovation, and also deliver distinguished and durable financial results and long-term value to patients, customers, shareholders and the broader healthcare ecosystem."
Ullem has served as Edwards’ CFO since 2014. "We would like to once again thank Scott for his outstanding leadership, partnership and impact," Zovighian added. "His commitment to a thoughtful transition and his continued support as a strategic advisor in the months ahead reflects the discipline and continuity that have long defined Edwards’ approach to leadership. We are grateful for Scott’s numerous contributions over the years that have helped to strengthen our company both strategically and financially."
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
Story Continues
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements made by Mr. Zovighian regarding Mistras’ experience being instrumental to the Edwards strategy to deliver long-term value to our stakeholders, the commencement of Mistras’ appointment in May 2026 and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260504913321/en/
Contacts
Media: Amy Meshulam, media@edwards.com
Investors: Gerianne Sarte, investor_relations@edwards.com
View Comments
- Possible Bearish Signals With Edwards Lifesciences Insiders Disposing Stock
May 4, 2026
Over the past year, many Edwards Lifesciences Corporation (NYSE:EW) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more.
Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Edwards Lifesciences Insider Transactions Over The Last Year
In the last twelve months, the biggest single sale by an insider was when the Corporate Vice President of Strategy & Corporate Development, Donald Bobo, sold US$2.0m worth of shares at a price of US$83.84 per share. That means that an insider was selling shares at below the current price (US$83.98). When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. This single sale was just 13% of Donald Bobo's stake.
Edwards Lifesciences insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Check out our latest analysis for Edwards Lifesciences NYSE:EW Insider Trading Volume May 4th 2026
For those who like to find hidden gems this freelist of small cap companies with recent insider purchasing, could be just the ticket.
Edwards Lifesciences Insiders Are Selling The Stock
The last quarter saw substantial insider selling of Edwards Lifesciences shares. In total, Corporate Vice President of Strategy & Corporate Development Donald Bobo sold US$2.0m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.
Insider Ownership Of Edwards Lifesciences
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Edwards Lifesciences insiders own 0.2% of the company, currently worth about US$105m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
Story Continues
So What Do The Edwards Lifesciences Insider Transactions Indicate?
An insider hasn't bought Edwards Lifesciences stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. While conducting our analysis, we found that Edwards Lifesciences has 3 warning signs and it would be unwise to ignore these.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this freelist of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments
- Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue
May 2, 2026
CHICAGO, May 02, 2026--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting.
As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospective, 10-year data demonstrating the durability of Edwards’ RESILIA tissue and its role in lifetime management for patients with aortic stenosis. To date, more than 500,000 patients worldwide have been treated with Edwards’ surgical and transcatheter innovations featuring RESILIA tissue.
At 10 years, COMMENCE trial data showed that patients treated with Edwards’ surgical valves featuring RESILIA tissue experienced:
97.9% freedom from structural valve deterioration (SVD) 97.8% freedom from reoperation due to SVD 98.6% freedom from non-structural valve dysfunction (other than PVL) Sustained hemodynamic performance, including stable gradients and effective orifice area over time
For patients, long-term durability matters because it can reduce the likelihood of repeat procedures over a lifetime, helping preserve quality of life as life expectancy increases.
"These 10-year data from the COMMENCE trial suggest this tissue technology has the potential to change the way we think about durability in biological valves, including in younger patients," said Lars G. Svensson, MD, PhD, chief of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute and professor of surgery at Cleveland Clinic. "What is striking is the low rate of structural valve deterioration and need for reoperation, even though the trial enrolled younger patients who historically face higher risks of valve deterioration, underscoring the importance of long-term evidence when physicians are making treatment decisions with their patients."
For nearly 70 years, Edwards has led structural heart innovation, advancing evidence generation that has helped set the standard for evaluating valve performance, durability and treatment options in severe aortic stenosis. The COMMENCE trial builds on the totality of Edwards’ clinical evidence, reinforcing the durability of outcomes supporting its surgical and transcatheter therapies, including large, randomized, FDA-approved studies such as the PARTNER series of trials.
The PARTNER trial series advanced the field with long-term patient outcomes on treatment with SAPIEN TAVR and SAVR, with 10 years of follow-up data. The new COMMENCE trial data build on that foundation with the latest evidence on the long-term durability of RESILIA tissue.
Story Continues
RESILIA tissue was designed to enhance the durability of tissue valves by helping resist calcification, a leading cause of valve failure over time. The technology combines advanced calcium blocking processes with dry storage to support long-term valve performance.
"As patients live longer and expect to remain active, structural heart therapies must be designed with lifetime care in mind," said Bernard Zovighian, Edwards’ CEO. "The COMMENCE 10-year study is the latest addition to our breadth of long-term data reflecting our commitment to advancing durable valve technologies through continuous evidence development, so Heart Teams and patients can make informed decisions over time."
The COMMENCE aortic trial is an FDA-approved, pivotal, prospective, multicenter clinical study designed to evaluate the safety and effectiveness of a bioprosthetic valve with RESILIA tissue used in SAVR, with follow-up through 10 years. Safety endpoints were defined according to established guidelines and independently adjudicated.
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements made by Mr. Zovighian and statements regarding expected long-term durability and sustained performance, reduction of the likelihood of repeat procedures, therapies helping to preserve quality of life, outcomes of the surgical and transcatheter therapies, expectations for remaining active, and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, COMMENCE, PARTNER, RESILIA, and SAPIEN are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260502326120/en/
Contacts
Media: Maureen Ranney, media@edwards.com
Investors: Gerianne Sarte, investor_relations@edwards.com
View Comments
- Top Research Reports for Philip Morris, Honeywell & Starbucks
May 1, 2026
Friday, May 1, 2026
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Philip Morris International Inc. (PM), Honeywell International Inc. (HON) and Starbucks Corp. (SBUX), as well as a micro-cap stock United-Guardian, Inc. (UG). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Follow Record Close Mixed, Q1 Oil Earnings
Today's Featured Research Reports
Philip Morris’ shares have outperformed the Zacks Tobacco industry over the past six months (+17.7% vs. +15.3%). The company has been benefiting from strong pricing power and an expanding smoke-free portfolio. Philip Morris is making steady progress in its smoke-free transition, with IQOS, ZYN and VEEV supporting growth and margin expansion across markets.
In first-quarter 2026, net revenues rose 9.1% year over year, driven by higher combustible pricing and increasing smoke-free contributions, which generated 43% of total revenues. The company is also progressing on cost-saving initiatives, helping support profitability even as it continues to invest in innovation, marketing and commercial capabilities.
For 2026, adjusted earnings per share are likely to be $8.36-$8.51, up 10.9-12.9% year over year. However, the company faces ongoing declines in cigarette volume, weakness in its U.S. business and increasing regulatory pressures across key markets.
(You can read the full research report on Philip Morris here >>>)
Shares of Honeywell have outperformed the Zacks Diversified Operations industry over the past six months (+9.9% vs. +0.5%). The company’s strength in the commercial aviation and building automation businesses augurs well. The Aerospace unit is particularly strong, driven by strength in the defense business and growth in air transport flight hours. Strong demand across the commercial aviation OEM and aftermarket businesses is aiding the unit.
Honeywell also continues to reward shareholders, which adds to the stock’s appeal. While acquisitions have expanded its product range and geographic reach, they have increased the company’s balance sheet debt significantly as well.
However, weakness in the Process Automation and Technology segment, due to lower petrochemical catalyst shipments, is worrisome. Also, the company has been dealing with increasing operating costs, which might hurt its margins and profitability. Foreign currency translation remains an overhang.
(You can read the full research report on Honeywell here >>>)
Starbucks’ shares have outperformed the Zacks Retail - Restaurants industry over the past six months (+34.1% vs. +10.7%). The company reported solid second-quarter fiscal 2026 results, with earnings and revenues beating the Zacks Consensus Estimate and increasing on a year-over-year basis.
Starbucks is benefiting from steady International segment momentum, improving operational execution and meaningful progress under its “Back to Starbucks” turnaround plan. Growth in international markets, along with innovations in delivery and digital channels, added to the positives.
Going forward, Starbucks emphasizes operational efficiency, coffeehouse portfolio optimization and menu innovation to drive growth. Also, its focus on digital loyalty, new product platforms and partnerships bodes well. However, elevated coffee and tariff costs, and an uncertain macro environment are a concern.
(You can read the full research report on Starbucks here >>>)
Shares of United-Guardian have outperformed the Zacks Medical - Products industry over the past six months (+5.9% vs. -24%). This microcap company with a market capitalization of $32.76 million has its investment case hinge on a shifting mix between resilient healthcare-linked products and volatile cosmetic ingredients.
Pharmaceutical growth, driven by expanded formulary access and stronger distribution, is improving visibility and supporting long-term prescription demand. Medical lubricants provide stable, recurring revenue tied to healthcare utilization, helping offset cyclical swings. The balance sheet remains strong, enabling continued shareholder returns and reinvestment without leverage.
However, earnings are pressured by margin compression and a sharp decline in cosmetics. Recovery depends on improved channel execution and normalization of inventory trends. New product initiatives like Natrajel add diversification potential, but commercialization remains gradual, increasing reliance on core segments and execution amid supplier concentration and cost sensitivity.
(You can read the full research report on United-Guardian here >>>)
Other noteworthy reports we are featuring today include Suncor Energy Inc. (SU), Keysight Technologies, Inc. (KEYS) and Edwards Lifesciences Corp. (EW).
Mark Vickery
Senior Editor
Story Continues
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Philip Morris (PM) Benefits from Strong Smoke-free Revenues
Aerospace Technologies Unit Aids Honeywell (HON), Costs Hurt
Starbucks (SBUX) Banks on Turnaround Efforts, High Costs Ail
Featured Reports
Suncor Energy (SU) Benefits From Diversified Energy Operations
The Zacks analyst believes that Suncor Energy's diversified energy operations and integrated business model help it sustain stable margins and steady profitability.
Edwards (EW) Rides on Solid TMTT Sales Amid Dull Macro Scenario
The Zacks Analyst is impressed with Edwards' strong TMTT sales globally, which grew 51.9% year over year in first quarter. Recent dull macroeconomic trends remain as headwind for the company.jQuery35106793546197951355_1777559024105
Efficiency Initiatives Aid Citizens Financial (CFG), High Cost Ail
Per the Zacks analyst, Citizens Financial's focus on efficiency initiatives and inorganic growth moves support its financials. Yet, escalating expenses remain a concern.
Diversified Offerings Drive Omnicom (OMC) Amid High Competition
Per the Zacks analyst, Omnicom's diverse portfolio across domains reduces reliance on single revenue streams and ensures stability. Rising competition from other players is an overhang.
Strong Enrollment Aids Strategic Education's (STRA) Performance
Per the Zacks analyst, Strategic Education benefits from strong employer-affiliated enrollment and Sophia Learning subscriptions. Also, employer partnerships and productivity actions bode well.
New Upgrades
Keysight (KEYS) Rides on Strength in Communications Solutions Group
Per the Zacks analyst, rising investments in AI data centers, Edge AI, and next-generation wireless technologies will likely boost Keysight's prospects. Strong focus on innovation is a positive.
Diamondback (FANG) Drives Efficiency and Strong Returns
The Zacks analyst believes that Diamondback Energy's strong operational efficiency and cost control support higher returns and steady free cash flow, even in a lower commodity price environment.
New Downgrades
Elevated Expenses Likely to Mar Zscaler's (ZS) Profitability
Per the Zacks Analyst, elevated expenses for enhancing sales and marketing capabilities, along with increased investments in research and development, are likely to dampen Zscaler's profitability.
MongoDB (MDB) Faces Conversion Risks, Competition Intensifies
Per the Zacks analyst, MDB faces conversion uncertainty and extended sales cycles, while revenue concentration and cloud competition pressure pricing.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Honeywell International Inc. (HON) : Free Stock Analysis Report
Starbucks Corporation (SBUX) : Free Stock Analysis Report
Philip Morris International Inc. (PM) : Free Stock Analysis Report
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
Suncor Energy Inc. (SU) : Free Stock Analysis Report
Keysight Technologies Inc. (KEYS) : Free Stock Analysis Report
United-Guardian, Inc. (UG): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Global's Undervalued Small Caps With Insider Actions For May 2026
May 1, 2026
As global markets navigate a complex landscape marked by record highs in major U.S. stock indexes, driven by robust economic data and AI-linked stocks, small-cap companies are capturing investor interest amid resilient consumer demand and evolving geopolitical tensions. In this environment, identifying promising small-cap stocks involves considering factors such as strong earnings potential and strategic insider actions that align with broader market trends.
Top 10 Undervalued Small Caps With Insider Buying Globally
Name PE PS Discount to Fair Value Value Rating CellaVision 21.6x 4.0x 37.34% ★★★★★★ Security Bank 4.2x 0.9x 34.79% ★★★★★★ Timbercreek Financial 16.3x 10.2x 41.69% ★★★★★☆ Yellow Pages 10.2x 0.9x 41.37% ★★★★☆☆ Nexus Industrial REIT 9.6x 3.3x 3.49% ★★★★☆☆ Shoucheng Holdings 42.8x 9.2x 43.21% ★★★☆☆☆ Centurion 12.0x 4.1x -13.90% ★★★☆☆☆ East West Banking 3.4x 0.9x 9.56% ★★★☆☆☆ AB Dynamics NA 2.1x 38.85% ★★★☆☆☆ CapitaLand China Trust NA 3.8x -3.68% ★★★☆☆☆
Click here to see the full list of 153 stocks from our Undervalued Global Small Caps With Insider Buying screener.
Let's uncover some gems from our specialized screener.
Arena REIT
Simply Wall St Value Rating: ★★★★★☆
Overview: Arena REIT is a real estate investment trust focusing on investing in social infrastructure properties, with a market cap of A$1.69 billion.
Operations: Arena REIT generates revenue primarily through its investments in real estate, with a focus on maintaining a high gross profit margin, which was 92.42% as of the latest period. The company's cost structure includes cost of goods sold and minimal operating expenses, with significant non-operating expenses impacting net income margins.
PE: 8.8x
Arena REIT, a small-cap player in the real estate sector, has recently shown insider confidence with share purchases. Despite challenges, including a forecasted earnings decline of 5.9% annually over the next three years and reliance on external borrowing for funding, Arena's recent financials reveal strong performance: net income surged to A$109.66 million for H1 2025 from A$36.27 million previously. The company remains focused on strategic acquisitions and developments to enhance portfolio quality and long-term rent growth potential.
Click here to discover the nuances of Arena REIT with our detailed analytical valuation report. Evaluate Arena REIT's historical performance by accessing our past performance report.ASX:ARF Share price vs Value as at May 2026
Strike Energy
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Strike Energy is an Australian energy company focused on the exploration and development of gas projects, with a market cap of approximately A$1.22 billion.
Story Continues
Operations: Strike Energy's revenue model primarily revolves around its Walyering segment, with recent quarterly revenue reaching A$72.91 million. The company's cost of goods sold (COGS) for the same period was A$68.77 million, resulting in a gross profit margin of 5.68%. Operating expenses are significant, totaling A$128.51 million in the latest quarter, impacting net income figures negatively at -A$154.11 million for the period ending December 2025.
PE: -2.8x
Strike Energy, a smaller company in the energy sector, faces financial challenges with less than a year of cash runway and reliance on external borrowing. Despite these hurdles, revenue is expected to grow 18.67% annually. Recent changes include Ms. Michaela Stanton-Cook's appointment as Joint Company Secretary and its addition to the S&P/ASX Emerging Companies Index in March 2026. The company reported a net loss of A$12.27 million for H1 2026 but reduced losses compared to the previous year, signaling potential improvement ahead.
Delve into the full analysis valuation report here for a deeper understanding of Strike Energy. Explore historical data to track Strike Energy's performance over time in our Past section.ASX:STX Share price vs Value as at May 2026
East West Banking
Simply Wall St Value Rating: ★★★☆☆☆
Overview: East West Banking is a financial institution primarily engaged in retail, consumer, and corporate banking services, with a market capitalization of ₱25.43 billion.
Operations: The company's primary revenue streams are derived from consumer banking and retail banking, with significant contributions from corporate banking and treasury operations. The net income margin has shown variation over time, reaching 25.08% in the most recent period. Operating expenses include substantial general and administrative costs as well as sales and marketing expenses.
PE: 3.4x
East West Banking, a smaller player in the financial sector, recently saw its CEO Jerry Ngo purchase 95,900 shares for over PHP 1.04 million, signaling insider confidence. Despite grappling with a high bad loans ratio of 4.3%, the bank's net income grew to PHP 9.22 billion in 2025 from PHP 7.61 billion the previous year, reflecting strong operational performance. A dividend increase to PHP 0.82 per share further underscores management's commitment to shareholder returns amidst ongoing executive board changes and committee appointments announced in April 2026.
Dive into the specifics of East West Banking here with our thorough valuation report. Learn about East West Banking's historical performance.PSE:EW Share price vs Value as at May 2026
Taking Advantage
Click here to access our complete index of 153 Undervalued Global Small Caps With Insider Buying. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Curious About Other Options?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:ARF ASX:STX and PSE:EW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Barclays Lifts PT on Edwards Lifesciences Corporation (EW) Following Q1 Earnings
May 1, 2026
Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical device stocks to invest in right now. Barclays raised the price target on Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104 on April 27, reaffirming an Overweight rating on the shares. The rating update came after the company’s fiscal Q1 earnings, with the firm telling investors in a research note that Edwards Lifesciences Corporation’s (NYSE:EW) quarter showed share gains in Europe and the United States.Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone”
In its financial results for Q1 released on April 23, Edwards Lifesciences Corporation (NYSE:EW) reported that fiscal Q1 sales rose 16.7% to $1.65 billion, while constant currency sales grew 12.7%. TAVR sales in the quarter rose 14.4% to $1.20 billion, while constant currency sales grew 11.0%. The company further reported that fiscal Q1 TMTT sales reached $173 million, driven by repair and replacement therapies.
Edwards Lifesciences Corporation (NYSE:EW) raised FY26 constant currency sales growth guidance to 9% to 11% from 8% to 10%, and also raised the FY26 adjusted EPS guidance midpoint, with a new range of $2.95 to $3.05 from $2.90 to $3.05.
Edwards Lifesciences Corporation (NYSE:EW) is involved in patient-focused medical innovations for heart disease and critical care monitoring. The company’s products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. Its operations are divided into the following geographical segments: the United States, Europe, Japan, and the Rest of the World.
While we acknowledge the potential of EW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- How The Edwards Lifesciences (EW) Investment Story Is Shifting As Views On Growth Diverge
Apr 30, 2026
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Edwards Lifesciences just saw its modeled fair value edge from US$96.93 to US$96.96, a tiny move that still reflects fresh thinking about where the shares might reasonably trade. That small adjustment comes as research houses pull in different directions, with some lifting price targets by US$1 to US$6 and others trimming them by as much as US$13, all circling around questions of execution, growth, and risk. As you read on, you will see how to interpret these shifting targets and keep up with the evolving story around Edwards.
Stay updated as the Fair Value for Edwards Lifesciences shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Edwards Lifesciences.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
Barclays, Truist, Evercore ISI, BTIG, Baird and Piper Sandler have all lifted their price targets by US$1 to US$6, which signals continued interest in Edwards Lifesciences at current valuation levels. Several of these firms are focusing on Edwards' ability to execute on its pipeline, including areas like left atrial appendage closure that drew attention when Oppenheimer flagged competitive pressure for AtriCure. The upgrade from Wolfe Research in April points to a group of analysts that see room for Edwards to create value if it can deliver on product launches and maintain its position in core surgical franchises.
🐻 Bearish Takeaways
BofA, Mizuho, UBS, Truist, Goldman Sachs and Canaccord have all reduced their targets, with Goldman Sachs cutting by US$13. This highlights concern around how much investors are currently paying relative to execution risk. These cautious calls tend to focus on the balance between growth expectations and potential headwinds, including competition in areas like atrial appendage closure and the risk that new products may take time to scale.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NYSE:EW 1-Year Stock Price Chart
We've flagged 3 risks for Edwards Lifesciences. See which could impact your investment.
What's in the News
Edwards Lifesciences issued 2026 sales guidance, with expected second quarter total sales between US$1.66b and US$1.74b and full year total company sales between US$6.5b and US$6.9b. The company also provided 2026 earnings guidance, projecting first quarter total sales between US$1.55b and US$1.63b, a full year sales growth rate of 8% to 10%, and EPS of US$2.90 to US$3.05. New TRISCEND II data on the EVOQUE transcatheter tricuspid valve replacement system at ACC.26 showed two year results with near elimination of tricuspid regurgitation, improved quality of life, no added device related risk, and lower all cause mortality when accounting for patient crossover, supported by registry data from more than 1,000 patients. Edwards updated on its share repurchase program, reporting that from October 1, 2025 to December 31, 2025 it bought back 524,543 shares for US$39.8m, bringing total repurchases under the program to 47,329,908 shares for US$3,499.23m, or 7.86% of shares.
Story Continues
How This Changes the Fair Value For Edwards Lifesciences
Fair value in the model moved from US$96.93 to US$96.96. Revenue growth assumption shifted from 9.94% to 9.56%. Net profit margin assumption moved from 25.09% to 25.75%. Future P/E assumption changed from 33.81x to 31.73x. Discount rate in the model moved from 7.81% to 7.84%.
Never Miss an Update: Follow The Narrative
Narratives connect Edwards Lifesciences' product pipeline, risks, and assumptions to a forward looking earnings profile and modeled fair value. They refresh as new clinical data, guidance, or market developments come through so you can see how the story changes over time.
Head over to the Simply Wall St Community and follow the Narrative on Edwards Lifesciences to stay up to date on:
How TAVR, EVOQUE, and Sapien M3 are expected to expand treatment options and support multi year revenue opportunities across a range of structural heart therapies. The role of RESILIA tissue technology, guideline changes, and global therapy adoption in the assumptions for higher margins and wider use of Edwards' cardiovascular products. Key risks around tariffs, the JenaValve acquisition, competitive pressure in markets such as Japan, and higher R&D and investment spend that could weigh on margins if growth assumptions are not met.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include EW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
Apr 28, 2026
IRVINE, Calif., April 28, 2026--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026.
Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day.
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260428779275/en/
Contacts
Media Contact: Amy Meshulam, media@edwards.com
Investor Contact: investor_relations@edwards.com
View Comments
